infertility/menopause Flashcards

1
Q

infertility

Etiology & Pathogenesis

A

To achievepregnancy
Female must be ovulatory with patentfallopian tubesand a receptiveuterus
Male must be able to produce sperm in adequate numbers that is capable of fertilizing the oocyte

Etiologies of couples
Female factor: 40%
Male factor: 40%
Unexplained infertility: 20%

Couples often have more than 1 contributing etiology
Both female and male factors: 35%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

infertitility

General

A

Inability of a couple to conceive:
After 12 months of timed, unprotected intercourse or donor insemination when the woman is < 35 years of age
After 6 months of timed, unprotected intercourse or donor insemination when the woman is> 35 years of age

Types:
Primary infertility
Couple has never conceived
Secondary infertility
Couple who have been able to get pregnant at least once, but now are unable
~80%–90% of healthy couples will conceive within 12 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

female fertility

general

A

A woman’s peak reproductive years are between the late teens and late 20s
By age 30, fertility starts to decline; with decline happening faster once a woman reaches their mid-30s
By 45, fertility has declined so much that getting pregnant naturally is unlikely

Categorized as:
Ovulatory dysfunction
Tubal factors
Uterine factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

female infertility

ovulatory dysfunction

A

Ovulatory dysfunction:
Etiologies
Hypogonadotropic hypogonadism:
Hypothalamusis not functioning properly
↓ Gonadotropin-releasing hormone (GnRH) → ↓ follicle-stimulating hormone (FSH) → ↓ oocyte maturation → anovulation (overexercise, eating disorders, stress)

Normogonadotropic normoestrogenic ovulatory dysfunction:
Normal GnRH and estrogens, but ↓FSH
Often oligomenorrhea and ↑androgens (PCOS)

Hypergonadotropic hypogonadism:
Ovaries not responsive toFSH
↑ GnRH → ↑FSH→ nonresponsiveovaries→ anovulation (Primary ovarian insufficiency (POI))

Oocyte aging
Fewer ovarian follicles that ovulate (atresia) →↓ estrogens
Estrogen normally inhibits FSH, but when levels are low there will be increased FSH
Diminished capacity to secrete inhibin
Inhibin decreases the release of FSH from the anterior pituitary (negative feedback)

Hyperprolactinemia
↑ Prolactin causes ↓ GnRH release

Hypothyroidism
Low levels of thyroid hormone can interfere with the release of an egg from the ovary

Estrogen- or androgen-secreting tumors
Sex cord-stromal tumors
Adrenal tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

female infertility

Tubal factors

A

Prevention of sperm reaching the egg

Occlusion (usually from adhesions)
Inflammation

Pelvic inflammatory disease - major causes include chlamydia orgonorrhea

Hydrosalpinges
Blockage of the distal fallopian tube with the accumulation of clear or serous fluid

Endometriosis
Fertility challenges due to both tubal adhesions and inflammation

Prior tubal surgery
Priorectopic pregnancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

female infertility

uterine factors

A

Uterine factors:
Impairedimplantation
Mechanical issues

↓ Endometrial receptivity
Causes
Leiomyoma (uterine fibroids) that impinge on uterine cavity
Endometrial polyps
Adhesions from prior surgery
Müllerian anomalies (septateuterus)
Stenosis of the cervix

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

male infertility

Endocrine and systemic disorders:

A

Congenital/genetic causes
Hypogonadotropic hypogonadism due to decreased secretion of gonadotropin-releasing hormone (GnRH) by the hypothalamus

Genetic defects affecting gonadotropins
Klinefelter syndrome(47,XXY): one of the most common causes ofprimary hypogonadismin men

Acquired conditions leading to hypothalamic or pituitarydysfunction
Hyperprolactinemia (medication induced)
Thyroid disorders
Hormone-secreting tumors

Systemic diseases – cystic fibrosis, diabetes
Obesity (can ↓testosteroneand testicular function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

male infertility

Testicular defects in spermatogenesis

A

Azoospermia: no sperm in the ejaculate

Oligospermia: ↓ sperm count
In 80% of infertile men
The most common cause of infertility in men

Asthenospermia: ↓ spermmotility
Occurs when less than 32% of sperm in a sample are able to move efficiently

Teratospermia: ↑ number of sperm with abnormal morphology

Cryptorchidism:undescended testes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

male infertility

Male etiologies and pathophysiology

A

Acquired causes
Varicocele – what side is most common?
Infection
Mumps
Gonorrhea and chlamydia
Chemotherapy
Radiation
Many cases are idiopathic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

male infertility

Sperm transport andsexual dysfunction disorders

A

Congenital abnormalities, dysfunction, or obstruction
Epididymis
Vas deferens
Ejaculatory ducts
Sexual dysfunction
Erectile dysfunction (ED)
Ejaculatory dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

female infertility

Patients do not fit the defined criteria for infertility, but have at least one identifiable infertility factor, they still qualify for a basic infertility workup

A

Age ≥ 40 years
Oocyte quantity and quality decline over time
Amenorrhea
No menstrual bleeding for 3 months in individuals with previously regular cycles
No menstrual bleeding for 6 months in those with previously irregular cycles
Known or suspected uterine, tubal, or peritoneal disease
Stage 3 or 4 endometriosis
Cause inflammation and scarring that alter pelvic anatomy
Suspected male factor infertility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

female infertility

labs

A

Laboratory tests:
Cycle day 3FSH,LH, andestradiol
↓FSHwith ↓ estrogen → functional hypothalamic amenorrhea
LH:FSHratio > 2 with normal estrogen →PCOS
↑FSHwith ↓ estrogen → POI
↓FSHwith ↑ estrogen → estrogen secreting tumor

Cycle day 21(mid-luteal) progesterone
↑Progesteronein theluteal phase confirms ovulation

↑ Prolactin → hyperprolactinemia

↑Thyroid-stimulating hormone→ hypothyroidism

↑ Testosterone →PCOS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

female infertility

imaging

A

Ultrasound (transvaginal)
Antral follicle count (assessment of ovarian reserve)
Leiomyomas
Polycystic-appearingovaries
Ovarian tumors

Saline infusionsonogram(SIS)
Injection of saline into the uterine cavity to distend it duringsonography
Aids in the diagnosis of uterine factors - polyps, uterine septa, etc.

Hysterosalpingogram
Inject radiopaque dye into the uterine cavity underfluoroscopy
Bilateral “fill and spill” of dye confirms tubal patency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

male infertility

Semen analysis (normal parameters listed):

A

Volume: 1.5-5.0 mL
pH: > 7.2
Concentration (density): > 15 million/mL
Number of sperm found in one milliliter of a semen sample

Count: > 40 million/mL
Motility: 40%
Morphology: > 4% normal

Agglutination: < 2
Motile spermatozoa stick to each other, head to head, midpiece to midpiece, tail to tail, or mixed
Due to semen antibodies

Liquefaction: 15-30 minutes
Semen is initially thick; liquefies (watery consistency) to help sperm motility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

male infertility

Laboratory and imaging ifsemen analysisis abnormal:

A

FSH,LH, and morning totaltestosterone
↑FSHandLHwith ↓testosterone→ hypergonadotropic hypogonadism (testicular defects)
Normal or ↓FSHandLHwith ↓testosterone→ hypogonadotropic hypogonadism (hypothalamic or pituitary defects)

↓ LHwith ↑ musclemass→ suspect androgen abuse
Scrotal and transrectal ultrasound

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

infertility

lifestyle factors

A

Coital frequency of every 1–2 days aroundovulation
Smokingcessation
Limitexcessive alcohol andcaffeineintake
Fertility-friendly lubricants (many common brands inhibit spermmotility)
Weight lossin the case ofobesityor overweight women
Weight gain for women who are underweight
Surgical correction of uterine anomalies

16
Q

infertiltiy - management

Clomiphene citrate

Ovulation induction, ovarian hyperstimulation, and insemination

A

Clomiphene citrate:
Selective estrogenreceptormodulator → ↓pituitaryinhibition → ↑FSH
Used in normogonadotropic normoestrogenic ovulatory dysfunction

Requirements:
Ovaries capable of normal function
Patent tubes
Sperm

Injectable gonadotropins (FSH)
High risk of multiples
Used in egg retrieval prior toin vitro fertilization (IVF)

17
Q

female fertility - management

insemination and in vitro

Ovulation induction, ovarian hyperstimulation, and insemination

A

Intrauterine insemination (IUI)
Injection of a processed semen sample into theuterus
Often combined withovulationinduction to ↑ pregnancy rates

In vitrofertilization
For patients with:
Failedovulationinduction/IUI
Severe tubal disease
Advanced age

Procedure:
Oocytesare surgically retrieved using ultrasound guidance

Fertilizationoccurs via:
Introduction of sperm from a semen sample
Embryos are cultivated in a Petri dish and reimplanted into theendometrium

18
Q

Menopause

general

A

Physiologic process in women characterized by the permanent cessation ofmenstruationthat occurs after the loss of ovarian activity (decreased estrogen production)
Epidemiology
Average age: 51 years
Typical range: 44–55 years of age (95% of women)

19
Q

Perimenopause

general

A

Transitional period (2-8 years) from reproductive to nonreproductive stage marked by menstrual irregularity and fluctuating hormone levels

20
Q

menopause

physiology

A

Hormone levels fluctuate significantly in the perimenopausal period

Perimenopause FSH
IncreasedFSH due to
↓ inoocytesdue to progressive degeneration of ovarian follicles that do not ovulate (atresia) →↓ estrogens
What does estrogen do to FSH prior to perimenopause?
Aging oocytes exhibit diminished capacity to secrete inhibin
During the perimenopausal period, women can still become pregnant; often ovulate twice → twin pregnancy

Primaryestrogenswitches fromestradiol toestrone
Estradiol(E2)
Primaryestrogenin premenopausal women
Starts to decrease within 1 year of menopause
Produced inovaries
Estrone(E1)
Primaryestrogenin postmenopausal women
Produced primarily inadipose tissue

21
Q

Perimenopause

Clinical Presentation

A

Symptoms are caused by fluctuating hormone levels

Menstrual changes:
Late reproductive years
Menstrual cycles shorten (cycles get closer)
Menopausal transition
Shorter cycles → longer cycles → very irregular/sporadiccycles → final menstrual period

Emotional symptoms:
Mood swings and irritability
Stress andanxiety

Vasomotor symptoms:
Hot flushes
Occur in 50%–90% of women
Usually last 1–5 minutes, but may last up to 45 minutes
Night sweats
Can significantly disruptsleep→chronic fatigue

Symptoms related to sexual function:
Genitourinary syndrome of menopause (GSM):
Vulvovaginalatrophy
Vaginal dryness and itching
Dyspareunia

22
Q

Postmenopause

S/Sx

A

Bone loss:
Osteoporosis → fragility fractures

Cardiovascular disease:
Lipid profiles worsen (↑cholesterol)
Weight gain
↑ Risk formyocardial infarctionand thromboembolic events

Hair, muscle, andskinchanges:
Hair thins
Skin becomes drier and rougher
↓Leanmassandmuscle tone
↑ Fatmass

Symptoms of GSM:
Dryness/dyspareunia
↑ Risk ofpelvic organ prolapse
Incontinence issues
↑Urinary tract infections(UTIs)

23
Q

Perimenopause

Dx

A

Primarily clinical

Pelvic exam
Assess vaginalatrophyin context of sexual complaints

Routine lab evaluation NOT indicated
FSH,LH, andestrogenlevels fluctuate significantly and are not clinically useful in most cases
Exception: if patient is around age of menopause with abnormal bleeding, ↑FSHmay be helpful in clarifying menopausal status

24
Q

peri/ppost menopause

management

A

Majority of women inperimenopauseand postmenopause do not require treatment

Primary goals
Relief of bothersome symptoms

Ensuring health through appropriatescreening
Cervical cytology: up to age 65/every 3 years
Diabetes testing: at age 45/every 3 years
Colonoscopy: at age 45/every 10 years
Mammography: at age 40 or 50/annually
Bone mineral density: at age 65/every 2 years if risk factors present

25
Q

Hormone Replacement Therapy (HRT)

candidates for tx

A

Controversial – 1990s clinical trials showed greater detrimental effects than beneficial effects

Use lowest dose for shortest duration required to treat symptoms

Candidates for therapy
Patientswithin 10 years of menopause
Patients< 60–65 years of age
Symptoms severe enough toaffectqualityof life
No contraindications

26
Q

Hormone replacement therapy (HRT)

Estrogen

A

Effective for treating
Vasomotor symptoms:hot flushes, night sweats →sleepdisturbances
Mood symptoms in perimenopause, but not postmenopause
GSM: vaginal dryness,dyspareunia
Routes of therapy:
Systemic therapy: oral, transdermalpatches, topical gels
Vaginal therapy: creams, vaginal tablets, ring
Estrogen stimulatesendometrium→ progestin required if patient hasuterus

27
Q

HRT

Progestin

A

Higher risk of adverse events thanestrogentherapy
Required for endometrial protection in patients withuterus
Selectionof route and dosing:
Usually oral
Give cyclically if still menstruating regularly
Give continuously if post-menopausal

28
Q

menopause

Contraindications toHRT

A

Hormone-sensitivebreast cancer
High-riskendometrial cancer
Unexplained vaginal bleeding
Cardiovascular disease
Venous thromboembolism
Stroke ortransient ischemic attack(TIA)
Acute liver disease

29
Q

Menopasue

Other management options - Vasomotor symptoms

A

Selective estrogen receptor modulators(SERMs)
Modulate effects ofestrogen
Ability to bind and activate estrogen receptors but act as either an agonist or antagonist depending on the tissue type

Non-hormonal medications
Selective serotonin reuptake inhibitors(SSRIs):
Paroxetineis the only FDA-approved SSRI
Serotonin-norepinepherine reuptake inhibitors (SNRIs)
Gabapentin
Clonidine

Lifestyle changes
Layered clothing
Maintain lower ambient temperature at home
Avoid alcohol andcaffeine
Stress management

30
Q

genitourinary syndrome of menopause

Management options

A

Low-dose vaginalestrogen
Most effective treatment
Doses are low enough that progestins arenotrequired for endometrial protection

Vaginal lubricants
Vaginal moisturizers
Regularsexual activity